



STATE OF WEST VIRGINIA
DEPARTMENT OF HUMAN SERVICES
BUREAU FOR MEDICAL SERVICES

Christina Mullins, MA
Acting Cabinet Secretary

Christy D. Donohue, CMC
Commissioner

Beneficiary Access to Care for Cell and Gene Therapy (CGT) Access Model

West Virginia Medicaid is participating in the Center for Medicare and Medicaid Services (CMS) Cell and Gene Therapy (CGT) Access Model effective January 1, 2026. The CGT Access Model is a federal initiative by CMS to expand access to high-cost, potentially curative gene therapies for Medicaid beneficiaries. The initial focus of the model is on FDA-approved gene therapies for sickle cell disease (SCD), specifically Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel). Additional information from CMS on the model can be found here: [CGT Access Model Frequently Asked Questions](#)

Contact Information

Participating Providers and Treatment Centers with questions regarding CGT Model access should direct questions to the following. Responses pertaining to Single Case Agreements and Provider Enrollment can be expected within 5 business days and decisions will be rendered within 14 days.

Single Case Agreements (SCA)

- Lisa Toms
 - Email: Lisa.A.Toms@wv.gov
 - Phone: 304-558-1700

Prior Authorizations (PA)

- Rational Drug Therapy Program (RDTP)
 - Email: RationalDrug@hsc.wvu.edu
 - Phone: 1-800-847-3859

Provider Enrollment

- Gainwell Technologies Provider Enrollment Department
 - Email: WVProviderEnrollment@gainwelltechnologies.com
 - Phone: 1-888-483-0793
 - Website: <https://www.wvmmis.com/Provider-Enrollment>

